The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression

Biomaterials

Volumn 34, Issue 9, 2013, Pages 2327-2339

  Zhu, Saijie ^a   Wonganan, Piyanuch ^a   Lansakara P , Dharmika S P ^a   O'Mary, Hannah L ^a   Li, Yue ^b   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cell uptake; DFdCTP dNTP ratio; Hydrazone; Intracellular metabolism; Lysosomes; Nucleoside analogs

Indexed keywords

CELL UPTAKE; DFDCTP/DNTP RATIO; HYDRAZONES; INTRACELLULAR METABOLISM; LYSOSOMES; NUCLEOSIDE ANALOGS;

BIOMOLECULES; CHEMOTHERAPY; MICELLES; POLYETHYLENE GLYCOLS; STEARIC ACID;

DRUG PRODUCTS;

4 N STEAROYL GEMCITABINE; ANTINEOPLASTIC AGENT; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; MACROGOL; PRODRUG; PYRIMIDINE NUCLEOSIDE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMICAL BOND; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG CONJUGATION; DRUG METABOLISM; DRUG SENSITIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROLYSIS; HYDROPHILICITY; HYDROPHOBICITY; LIPOPHILICITY; LIPOSOMAL DELIVERY; LUNG CANCER; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON TRANSPORT; WESTERN BLOTTING; ZETA POTENTIAL;

ACIDS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICELLES; NANOTECHNOLOGY; RIBONUCLEOTIDE REDUCTASES;

EID: 84872386589     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.053     Document Type: Article

References (47)

1. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs 1999, 22:176-183.
2. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349-4357.
3. Bouffard D.Y., Laliberte J., Momparler R.L. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993, 45:1857-1861.
4. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995, 6(Suppl. 6):7-13.
5. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110-6117.
6. Andersson R., Aho U., Nilsson B.I., Peters G.J., Pastor-Anglada M., Rasch W., et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 2009, 44:782-786.
7. Seve P., Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005, 5:73-88.
8. Goan Y.G., Zhou B., Hu E., Mi S., Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999, 59:4204-4207.
9. Nakahira S., Nakamori S., Tsujie M., Takahashi Y., Okami J., Yoshioka S., et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007, 120:1355-1363.
10. Reddy L.H., Dubernet C., Mouelhi S.L., Marque P.E., Desmaele D., Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 2007, 124:20-27.
11. Rejiba S., Reddy L.H., Bigand C., Parmentier C., Couvreur P., Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 2011, 7:841-849.
12. Allain V., Bourgaux C., Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res 2012, 40:1891-1903.
13. Chung W.G., Sandoval M.A., Sloat B.R., Lansakara P.D., Cui Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release 2012, 157:132-140.
14. Wonganan P, Lansakara-P DSP, Sandoval MA, Zhu S, Cui Z. Mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. AAPS Annual Meeting and Expositoin, Chicago, IL, USA, October 14-18, 2012.
15. Kim S., Shi Y., Kim J.Y., Park K., Cheng J.X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv 2010, 7:49-62.
16. Liggins R.T., Burt H.M. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 2002, 54:191-202.
17. Boudier A., Aubert-Pouessel A., Louis-Plence P., Gerardin C., Jorgensen C., Devoisselle J.M., et al. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 2009, 30:233-241.
18. Chen W., Meng F., Cheng R., Zhong Z. pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 2010, 142:40-46.
19. Zhang C.Y., Yang Y.Q., Huang T.X., Zhao B., Guo X.D., Wang J.F., et al. Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery. Biomaterials 2012, 33:6273-6283.
20. Zhu S., Lansakara P.D., Li X., Cui Z. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. Bioconjug Chem 2012, 23:966-980.
21. Wang Y., Li L., Jiang W., Yang Z., Zhang Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 2006, 16:2974-2977.
22. Breyer S., Effenberger K., Schobert R. Effects of thymoquinone-fatty acid conjugates on cancer cells. ChemMedChem 2009, 4:761-768.
23. Rasras A.J., Al-Tel T.H., Al-Aboudi A.F., Al-Qawasmeh R.A. Synthesis and antimicrobial activity of cholic acid hydrazone analogues. Eur J Med Chem 2010, 45:2307-2313.
24. Kono K., Kojima C., Hayashi N., Nishisaka E., Kiura K., Watarai S., et al. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials 2008, 29:1664-1675.
25. Aguiar J., Carpena P., Molina-Bolívar J.A., Carnero Ruiz C. On the determination of the critical micelle concentration by the pyrene 1:3 ratio method. J Colloid Interface Sci 2003, 258:116-122.
26. Zhu S., Hong M., Zhang L., Tang G., Jiang Y., Pei Y. PEGylated PAMAM dendrimers-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res 2010, 27:161-174.
27. Hsu S.H., Ho T.T., Tseng T.C. Nanoparticle uptake and gene transfer efficiency for MSCs on chitosan and chitosan-hyaluronan substrates. Biomaterials 2012, 33:3639-3650.
28. Peng S.F., Su C.J., Wei M.C., Chen C.Y., Liao Z.X., Lee P.W., et al. Effects of the nanostructure of dendrimer/DNA complexes on their endocytosis and gene expression. Biomaterials 2010, 31:5660-5670.
29. Axline S.G., Reaven E.P. Inhibition of phagocytosis and plasma membrane mobility of the cultivated macrophage by cytochalasin B. Role of subplasmalemmal microfilaments. J Cell Biol 1974, 62:647-659.
30. Decosterd L.A., Cottin E., Chen X., Lejeune F., Mirimanoff R.O., Biollaz J., et al. Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal Biochem 1999, 270:59-68.
31. Losa R., Sierra M.I., Gion M.O., Esteban E., Buesa J.M. Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 840:44-49.
32. Harnsberger H.F., Cochran E.L., Szmant H.H. The basicity of hydrazones. J Am Chem Soc 1955, 77:5048-5050.
33. Kalyanasundaram K. Pyrene fluorescence as a probe of fluorocarbon micelles and their mixed micelles with hydrocarbon surfactants. Langmuir 1988, 4:942-945.
34. Sloat B.R., Sandoval M.A., Li D., Chung W.G., Lansakara P.D., Proteau P.J., et al. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm 2011, 409:278-288.
35. Immordino M.L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004, 100:331-346.
36. Pandit N.K. Membranes and tissues. Introduction to the pharmaceutical sciences 2007, 65. Lippincott Williams & Wilkins, Philadelphia. N.K. Pandit (Ed.).
37. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766.
38. Cao M.Y., Lee Y., Feng N.P., Xiong K., Jin H., Wang M., et al. Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res 2003, 9:4553-4561.
39. Bergman A.M., Eijk P.P., Ruiz van Haperen V.W., Smid K., Veerman G., Hubeek I., et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65:9510-9516.
40. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 2005, 94:1782-1793.
41. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
42. Bae Y., Alani A.W., Rockich N.C., Lai T.S., Kwon G.S. Mixed pH-sensitive polymeric micelles for combination drug delivery. Pharm Res 2010, 27:2421-2432.
43. Kim D., Lee E.S., Oh K.T., Gao Z.G., Bae Y.H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 2008, 4:2043-2050.
44. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
45. Adar Y., Stark M., Bram E.E., Nowak-Sliwinska P., van den Bergh H., Szewczyk G., et al. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis 2012, 3:e293.
46. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
47. Jones R.J., Baladandayuthapani V., Neelapu S., Fayad L.E., Romaguera J.E., Wang M., et al. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 2011, 118:4140-4149.